Clinical trials: Childhood Neoplasm
Cancer, Neoplasm
Treatment of Patients With Cancer With Genetically Modified Salmonella Typhimurium Bacteria
This study will examine the safety and toxicities of intravenously administering a genetically modified type of Salmonella bacteria (VNP20009) and its impact on tumor growth in advanced or metastatic cancer (cancer that has…
- Conditions
- Cancer, Neoplasm, Neoplasm Metastasis
- Trial name
- NCT00004988
- Testing
- VNP20009
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer, Endometrial Neoplasm
Precision Medicine Applied to the Study of Endometrial Cancer: Application of NGS for Molecular Classification
In recent years, knowledge about cancer biology has expanded significantly. The study of gene expression profiles has revealed the heterogeneous nature and potential reclassification of the various tumor subtypes based on…
- Trial name
- NCT07006103
- Volunteers
- 400 people
- Sponsor
- Hospital Italiano de Buenos Aires
Prostate Cancer
TAK-700 in Castration Resistant Prostate Cancer
The objective of this randomized phase II open label trial is to determine the anti-tumor activity of TAK-700 (Orteronel) as compared to bicalutamide in terms of clinical progression-free survival in prostate cancer patients who…
- Trial name
- NCT01658527
- Testing
- Orteronel, Bicalutamide
- Where
- 4 sites in Belgium
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment.
- Trial name
- DiRECT (NCT05364086)
- Testing
- Biospecimen Collection, Electronic Health Record Review, Interview
- Where
- 259 sites in United States
- Volunteers
- 2,100 people
- Sponsor
- University of Rochester NCORP Research Base
Breast Cancer
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before.
- Trial name
- NCT03734029
- Testing
- Trastuzumab deruxtecan (DS-8201a), Capecitabine, Eribulin
- Where
- 208 sites in United States, Austria and 18 more
- Volunteers
- 557 people
- Sponsor
- Daiichi Sankyo
Leukemia
Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill leukemia cells.
- Trial name
- NCT00005802
- Testing
- aldesleukin, filgrastim, therapeutic allogeneic lymphocytes
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Pancreatic Cancer
Huachansu & Gemcitabine in Pancreatic Cancer
This protocol is part of a larger grant funded by the NCI to create an international research center to study traditional Chinese medicine (TCM).
- Trial name
- NCT00837239
- Testing
- Gemcitabine, HuaChanSu
- Where
- China
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- EXCEED (NCT06238479)
- Testing
- LY4101174
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 490 people
- Sponsor
- Eli Lilly and Company
Myeloproliferative Neoplasm
A New Blood Score for Myelofibrosis Staging
BCR:ABL1 negative myeloproliferative neoplasms (MPN) include three entities: polycythemia vera, essential thrombocythemia and primitive myelofibrosis.
- Trial name
- FIBROMOELLE (NCT06177366)
- Testing
- Blood sampling
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm
Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency Medicine During the COVID-19 Pandemic
This study investigates patients' perceptions of their doctor's or nurse's empathy during an in-person interaction with the doctor or nurse wearing personal protective equipment (PPE) compared to during a video interaction with…
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT05102656
- Testing
- Best Practice, Discussion, Questionnaire Administration
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- M.D. Anderson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Personalized NK Cell Therapy in CBT
This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT02727803
- Testing
- Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreas Cancer, Pancreas Neoplasm
Patient-derived Organoids Drug Screen in Pancreatic Cancer
Few chemotherapeutic options exist for pancreatic cancer. Moreover, objective criteria are lacking for deciding which regimen is more beneficial for patient presenting with metastases at diagnosis.
- Conditions
- Pancreas Cancer, Pancreas Neoplasm, Pancreas Adenocarcinoma, Pancreatic Cancer
- Trial name
- NCT05351983
- Testing
- Surgical biopsy of tumoral tissue for organoid generation
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- Prof. Dr. med. Dres. h.c. Jan Schmidt, MME
Maxillofacial Bone Defects, Alveolar Bone Atrophy
Gene-activated Matrix for Bone Tissue Repair in Maxillofacial Surgery
The purpose of this study is to evaluate safety and efficacy of gene-activated matrix ("Nucleostim") for regeneration of bone tissue in maxillofacial area.
- Conditions
- Maxillofacial Bone Defects, Alveolar Bone Atrophy, Jaw Fractures, Maxillofacial Bone Deformities
- Trial name
- NCT02293031
- Testing
- Gene-activated matrix "Nucleostim"
- Where
- 2 sites in Russia
- Volunteers
- 12 people
- Sponsor
- NextGen Company Limited
Papillary Thyroid Cancer, Papillary Carcinoma
More Than 50% of Unifocal cN0 T1b/Small T2 Papillary Thyroid Carcinoma May Require Completion Thyroidectomy if Nodal Status is Evaluated
In absence of nodal metastases or aggressive features, thyroid lobectomy (TL) should be preferred over total thyroidectomy (TT) for small unifocal papillary thyroid carcinoma (PTC).
- Conditions
- Papillary Thyroid Cancer, Papillary Carcinoma, Thyroid Cancer, Thyroid Carcinoma
- Trial name
- cN0PTC (NCT06439745)
- Volunteers
- 314 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lymphoblastic Leukemia, Acute, Childhood
N-Acetylcysteine vs Placebo as Adjunctive Treatment in Pediatric Leukemia
The goal of this clinical trial is to analyze the effect of N-Acetylcysteine administration towards blood oxidant level, transaminase enzyme, and bilirubin level in ALL children who undergo induction phase of chemotherapy.
- Trial name
- NCT05611086
- Testing
- N-Acetylcysteine
- Where
- Indonesia
- Volunteers
- 16 people
- Sponsor
- Teny Tjitra Sari
Malignant Head and Neck Neoplasm, Malignant Neoplasm
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
The main goal of this phase of the study is to determine if objectively assessed Physical Activity (PA) levels in advanced-cancer patients are associated with health care provider (HCP)-assessed ECOG performance status and…
- Conditions
- Malignant Head and Neck Neoplasm, Malignant Neoplasm, Metastatic Malignant Neoplasm in the Neck, Metastatic Malignant Neoplasm in the Uterine Cervix
- Trial name
- NCT01365169
- Testing
- Exercise Intervention, Health Telemonitoring, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 590 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma, Medulloblastoma
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Indoximod was developed to inhibit the IDO (indoleamine 2,3-dioxygenase) enzymatic pathway, which is important in the natural regulation of immune responses.
- Conditions
- Glioblastoma, Medulloblastoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
- Trial name
- NCT04049669
- Testing
- Indoximod, Partial Radiation, Full-dose Radiation
- Where
- 5 sites in United States
- Volunteers
- 130 people
- Sponsor
- Theodore S. Johnson
Invasive Breast Cancer, Ipsilateral Recurrence
Sentinel Lymph Node Procedure in Ipsilateral Invasive Breast Cancer Relapse
Sentinel lymph node biopsy (SLNB) has become the standard procedure for staging of patients with clinically node-negative breast cancer.
- Conditions
- Invasive Breast Cancer, Ipsilateral Recurrence, Sentinel Lymph Node Biopsy
- Trial name
- FIGARO (NCT03630653)
- Testing
- Sentinel LN in breast cancer recurrence
- Where
- 9 sites in France
- Volunteers
- 50 people
- Sponsor
- Institut Cancerologie de l'Ouest
Brain Tumors, Central Nervous System Tumors
Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors
RATIONALE: Analyzing the number and structure of genes found in a child's cancer cells may help doctors improve methods of diagnosing and treating children with brain tumors.
- Trial name
- NCT00003096
- Testing
- DNA ploidy analysis, comparative genomic hybridization, cytogenetic analysis
- Where
- 61 sites in United States, Australia and 1 more
- Volunteers
- 88 people
- Sponsor
- Children's Oncology Group
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced…
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
- Trial name
- KontRASt-01 (NCT04699188)
- Testing
- JDQ443, TNO155, tislelizumab
- Where
- 38 sites in United States, Australia and 14 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.